Prevention of symptomatic patent ductus arteriosus with ethamsylate in babies treated with exogenous surfactant.

Machine translation Machine translation
作者 Amato M, Hüppi P, Markus D -More
类别 Primary study
期刊Journal of perinatology : official journal of the California Perinatal Association
Year 1993
連結 Pubmed
在与早产儿呼吸窘迫综合征的一些试验表明外源性表面活性物质治疗后的动脉导管未闭的发病率升高。后一种表面活性剂的制备猪气管内单剂量效应对动脉导管未闭的预防ethamsylate（固尔苏，2.5毫升/公斤）在20组研究早产儿严重呼吸窘迫综合症。病人的妊娠年龄为29.2 + / - 2.5周（平均+ / - 标准差），及出生体重为1158 + / - 319克。 Ethamsylate（12.5毫克/公斤）的范围内给予预防性生命的头4 4天6小时后每小时的剂量。动脉导管未闭血流动力学发生显着更频繁地在模型组（10 8）比ethamsylate组（10 2）性（P <0.02）。无急性副作用是由于治疗。这个初步的经验表明，ethamsylate，前列腺素合成的抑制剂，可以减少动脉导管未闭的发病率非常低出生体重与表面活性物质治疗儿动脉有益。
This translation has been produced by an automated software. If you wish to submit your own translation, please send it to translations@epistemonikos.org
Epistemonikos ID: 4f88849de65de0dc88e289f1d5e68489c1e77b5a
First added on: Jun 08, 2011
Warning
This is a machine translation from an article in Epistemonikos.

Machine translations cannot be considered reliable in order to make health decisions.

See an official translation in the following languages: English

If you prefer to see the machine translation we assume you accept our terms of use